UiPath (NYSE:PATH) Now Covered by Analysts at KeyCorp

Equities researchers at KeyCorp started coverage on shares of UiPath (NYSE:PATH - Get Free Report) in a report released on Monday, Marketbeat Ratings reports. The firm set an "overweight" rating and a $27.00 price target on the healthcare company's stock. KeyCorp's target price would indicate a potential upside of 24.68% from the company's current price.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $29.00 price target on shares of UiPath in a report on Monday, April 1st. Bank of America increased their target price on shares of UiPath from $26.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 14th. BMO Capital Markets lifted their price target on shares of UiPath from $24.00 to $28.00 and gave the stock a "market perform" rating in a report on Thursday, March 14th. Mizuho increased their price objective on UiPath from $22.00 to $25.00 and gave the company a "neutral" rating in a report on Thursday, March 14th. Finally, JPMorgan Chase & Co. upgraded UiPath from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $22.00 to $28.00 in a research note on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $27.41.

UiPath Stock Up 2.1 %

PATH stock traded up $0.45 during trading on Monday, reaching $21.66. The stock had a trading volume of 5,168,131 shares, compared to its average volume of 9,268,588. UiPath has a one year low of $12.38 and a one year high of $27.87. The company's 50 day moving average is $23.51 and its two-hundred day moving average is $21.25. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of -127.64 and a beta of 0.96.

UiPath (NYSE:PATH - Get Free Report) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. As a group, research analysts predict that UiPath will post -0.04 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Ashim Gupta sold 16,000 shares of the company's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the sale, the chief financial officer now owns 87,505 shares of the company's stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On UiPath

Institutional investors have recently added to or reduced their stakes in the business. Mark Sheptoff Financial Planning LLC bought a new position in shares of UiPath in the 4th quarter worth $25,000. HighMark Wealth Management LLC bought a new position in shares of UiPath during the 4th quarter valued at $27,000. Tyler Stone Wealth Management purchased a new position in UiPath in the 2nd quarter worth $28,000. Cypress Capital Management LLC WY purchased a new stake in UiPath during the fourth quarter valued at about $29,000. Finally, Fifth Third Bancorp increased its holdings in shares of UiPath by 2,005.3% in the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company's stock worth $34,000 after buying an additional 1,905 shares during the period. 62.50% of the stock is currently owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.